Exponent, Inc. (EXPO) Stock Price & How to Invest

Exponent, Inc. is a Menlo Park, California engineering and scientific consulting firm founded in 1967 that solves complex technical problems for corporations, law firms, insurers, and government agencies. Its two segments are Engineering and Other Scientific (roughly 85% of net revenues), covering failure analysis, product testing, user research, and disputes across consumer electronics, energy, utilities, transportation, and life sciences, and Environmental and Health (about 15%). The business is people-based rather than asset-based, so its economics revolve around billable hours, staff utilization, and realized billing rates, and its brand as a science-for-hire authority lets it command premium fees on reactive, high-stakes engagements.

For investors, Exponent is usually framed as a quality compounder: recurring demand tied to litigation, regulation, safety failures, and increasingly AI-enabled products supports steady mid-single to low-double-digit revenue growth, EBITDA margins near 28% of net revenues, and a shareholder-return model built on a growing dividend plus aggressive buybacks. The trade-off is that this quality is well recognized by the market, so the stock tends to carry a high earnings multiple that leaves limited room for disappointment if hiring, utilization, or billable-hour growth slows.

Exponent's output is entirely dependent on attracting and retaining specialized PhD-level and engineering talent, so wage inflation, attrition, or hiring shortfalls directly pressure capacity and margins. Utilization and billable hours can swing with client budgets and the timing of large disputes, making quarterly results lumpy. A meaningful portion of revenue is concentrated in a relatively small number of large engagements and clients, adding volatility. The stock also trades at a premium multiple (a trailing P/E in the low-to-mid 30s), so even modest growth disappointments can drive outsized share-price moves. Broader legal, regulatory, or economic slowdowns that reduce litigation and consulting spend would weigh on demand.

3 analysts publish price targets on EXPO, averaging $84.00 against a $70.30 price as of September 2026, or +19.5%. The published targets run from $72.00 to $90.00, a narrow spread, and the ratings split 3 buy, 1 hold, 0 sell. Over the last six months there has been 1 raise and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full EXPO forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Exponent, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Reactive and disputes demand. A large share of Exponent's work is reactive: product failures, accidents, recalls, and litigation that clients cannot defer. The most optimistic published target, $90.00, assumes this works close to its best case.

The case against. Exponent's output is entirely dependent on attracting and retaining specialized PhD-level and engineering talent, so wage inflation, attrition, or hiring shortfalls directly pressure capacity and margins. The most pessimistic target, $72.00, is roughly what EXPO is worth if this bites instead.

Read the full bull and bear case on EXPO, including what would have to change to break either one. Walnut is not an investment adviser.

Yes. Exponent, Inc. (EXPO) has had one share split in the last 10 years:

• 2:1 on June 8, 2018, so every share held became 2 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of EXPO the day before the 2:1 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Exponent, Inc.'s investor relations page or your broker.

• Revenue (TTM, gross): ~$580M
• Q1 2026 revenue: ~$166M (+14% YoY)
• Q1 2026 EPS (diluted): ~$0.59
• EBITDA margin (net rev.): ~28%
• Market cap: ~$2.8B
• Dividend yield: ~2%

Exponent's Q1 2026 revenue rose about 14% to roughly $166 million with net income up 11% to about $30 million, aided by 76% utilization and roughly 399,000 billable hours. The shares typically trade at a rich valuation, with a trailing P/E in the low-to-mid 30s, reflecting the market's view of the franchise as a durable, high-quality compounder. The company continues to return cash aggressively, paying dividends and repurchasing stock while expanding its buyback authorization.

Other names that sit close to EXPO: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get EXPO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so EXPO sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where EXPO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

EXPO is a niche, brand-driven consulting franchise with strong margins and consistent capital returns, and its investment story hinges on billable-hour growth and utilization holding up against a rich valuation.

Whether EXPO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is EXPO a buy or a sell?, and where the stock could go from here in the EXPO stock forecast.

For income investors, whether EXPO pays a dividend and how the payout looks is covered in does EXPO pay a dividend? And to weigh EXPO against a peer, read the full side-by-side comparisons: EXPO vs FCN and EXPO vs ECG.